A former payer chief medical officer on why behavioral addiction coverage stalled, what separates real outcomes data from marketing, and what the field still gets wrong about treating it.
Gambling disorder is recognized in the DSM-5-TR. Gaming disorder is recognized in ICD-11. Neither is reliably a covered benefit. That gap between clinical recognition and practical access is where Dr. Christopher Dennis has spent much of his career — as Chief Medical Officer of ValueOptions’ commercial division, on NCQA’s Standards Committee and as chair of its MBHO Advisory Committee, as Chief Behavioral Health Officer at Landmark Health within Optum, and as Chief Medical Officer of a national addiction treatment organization. He recently joined the Kindbridge Behavioral Health advisory board as Senior Clinical and Payer Strategy Advisor. We asked him what it actually takes to close that gap.
You have worked on nearly every side of behavioral health: payer chief medical officer, provider executive, founder, clinician, and investor. From which seat does Kindbridge look most interesting, and why?
Probably the payer seat, because payers do not need another broad behavioral health vendor. They need a partner that can solve a defined, under-addressed problem with credible clinical care, broad access, measurable outcomes, and operational reliability. Kindbridge is interesting because behavioral addictions sit in a growing gap between recognized clinical need and an inconsistent delivery and coverage system. My operator and investor experience still matters, though. The opportunity is not just being specialized. It is turning that specialization into a scalable, accountable model that a payer can confidently buy.
Historically, many payers treated behavioral addiction services as outside the core behavioral health benefit or too difficult to reimburse consistently. When you led ValueOptions’ commercial division, what drove that posture, and what has changed?
It was less a philosophical “no” than a structural one. Benefit language was inconsistent, coding was imperfect, qualified networks were thin, treatment pathways were not standardized, and the evidence was not packaged in a way that answered payer questions about utilization, outcomes, and cost. What has changed is the visibility and urgency of the problem. The mobile, always-on environment has made gambling and gaming-related harm harder to ignore, along with the links to depression, anxiety, substance use, financial crisis, and suicide. Coverage will move when providers can define the population, standardize care, and show measurable value.
Through your work with NCQA’s Standards Committee and MBHO Advisory Committee, you saw how behavioral health quality standards and measures are evaluated. What separates outcomes data that survives payer and academic scrutiny from data that merely looks good in a deck?
The denominator. That is where most attractive outcomes claims fall apart. I want to know who was included, who was excluded, how many patients completed follow-up, what happened to the people who disappeared, and whether the endpoints were defined before the analysis. The measures should be validated, collected at consistent intervals, clinically meaningful, and reproducible across populations. Symptom improvement matters, but payers also care about engagement, retention, crisis utilization, functional recovery, and total cost. A selective chart of successful completers is marketing. A transparent methodology that can be audited is evidence.

Gambling disorder is recognized in DSM-5-TR. Gaming disorder is recognized in ICD-11, while Internet Gaming Disorder remains a condition for further study in DSM-5-TR. Yet coverage remains inconsistent. Is this mainly a coding problem, an evidence problem, or a willingness problem?
All three, but the deeper issue is ownership. Coding alone does not create a benefit, and evidence alone does not create a network or a payment model. These conditions often fall between medical benefits, behavioral health, employee assistance programs, state-funded services, and industry-funded responsible gaming programs. When nobody clearly owns the problem, coverage remains fragmented. The field needs a usable diagnostic and coding framework, defined treatment pathways, qualified clinicians, measurable outcomes, and a clear economic case. Once a payer can see who should be treated, what care consists of, and what success looks like, willingness improves.
At Landmark, you helped build integrated, value-based behavioral health care at scale, including after the organization became part of Optum. Which elements of that model transfer to a specialty provider like Kindbridge, and which do not?
The transferable lesson is that behavioral health cannot sit in its own silo. At Landmark, we identified need proactively, brought care to the patient, worked across disciplines, and focused on the whole person rather than a diagnosis in isolation. That absolutely transfers. What does not transfer is the exact operating model. Landmark served a medically complex, high-risk population through intensive, longitudinal, often home-based care. Kindbridge should translate the principles, not copy the structure: targeted screening, rapid access, closed-loop referrals, coordination with primary care and psychiatry, clear escalation pathways, and outcomes that matter to both the patient and the payer.
You have led clinical operations at a national addiction treatment organization and practice telepsychiatry across multiple states. What does the field consistently misunderstand about treating behavioral addictions, as distinct from substance use disorders?
The field often takes a substance use treatment template and simply changes the noun. That misses important differences. The behavior may be legal, socially normalized, digitally accessible, and present in the patient’s pocket all day. Financial harm, secrecy, family disruption, and suicide risk can escalate before there are visible physical signs. Treatment has to address the behavior and the surrounding system: psychiatric comorbidity, motivation, cognitive distortions, digital and financial guardrails, family involvement, relapse planning, and practical protections such as self-exclusion. It also cannot become moralistic. These are clinical disorders, not failures of character.
You co-founded a venture-backed telepsychiatry company that was later acquired, and you invest in early-stage health companies. What do you look for in a behavioral health company that most people miss?
I look for the gap between the pitch and the actual delivery of care. A large market, attractive technology, and early engagement numbers are easy to present. The harder questions are who owns the budget, why they will pay, whether the clinical model improves an outcome that matters, and whether the company can deliver consistently at ten times the current scale. I look closely at licensure, reimbursement, clinician productivity, adverse-event management, retention after the novelty wears off, and the honesty of the data. I also watch how founders respond when evidence challenges their original thesis.
Five years from now, what does the version of this field that goes badly look like, and what does the version that goes right look like?
The bad version is a rapidly growing harm problem met by fragmented cash-pay apps, thin clinical models, sponsorship-driven programs, and outcome claims nobody can audit. AI gets used to automate engagement without improving accountability, and treatment remains separate from the rest of health care. The good version is very different: routine screening, earlier intervention, clear clinical pathways, qualified national networks, integrated psychiatric and therapeutic care, payer coverage, and real-world outcomes tied to function, safety, and cost. Technology should help identify risk and personalize care, but it should not replace clinical judgment or responsibility.
Kindbridge has broad national reach and Joint Commission accreditation. From a payer’s perspective, how much does accreditation move the needle, and what must sit behind it?
Accreditation matters because it tells a payer that an outside organization has evaluated the company’s governance, safety processes, and quality infrastructure. It can get you through an important first gate. It does not prove that the care works, and it does not earn a contract by itself. Behind it, a payer will still expect licensure and credentialing discipline, network adequacy, timely access, clinical protocols, crisis and escalation procedures, secure data exchange, claims capability, outcome reporting, and a credible cost and utilization story. Accreditation earns the right to be evaluated. Performance earns the partnership.
What made you say yes to this particular advisory role?
I said yes because the need is real, the category is underdeveloped, and Kindbridge is trying to build a real clinical and payer platform, not simply a referral directory or cash-pay therapy brand. The company has specialization, clinical infrastructure, research ambition, and the potential to become a meaningful payer partner. Just as important, there is actual work for me to do: help translate a credible clinical model into something payers can understand, measure, contract with, and scale. I am not interested in lending my name to a company that wants affirmation. I am interested when my experience can materially improve the outcome.
Christopher Dennis, MD, MBA, FAPA, joined the Kindbridge Behavioral Health advisory board in August as Senior Clinical and Payer Strategy Advisor. He is a board-certified psychiatrist and has served as Chief Medical Officer of ValueOptions’ commercial division, Chief Behavioral Health Officer at Landmark Health within Optum, and Chief Medical Officer of Pinnacle Treatment Centers. He co-founded the telepsychiatry company Minded, later acquired by UpLift, and serves on NCQA committees shaping behavioral health quality standards. Read the full announcement →
If gambling, gaming, or another compulsive behavior is affecting your life or someone you care about, Kindbridge offers confidential care from licensed clinicians. Book an appointment →
Health plans, employers, and benefits leaders: see how Kindbridge works with organizations →

